|
|
|
|
|
|
|
02.06.26 - 15:33
|
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) (GlobeNewswire EN)
|
|
|
BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising preliminary clinical data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), will be presented during a late-breaking session at the European Hematology Association (EHA) 2026 Congress, taking place June 11-14, 2026, in Stockholm, Sweden....
|
|
|
01.06.26 - 16:06
|
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026 (GlobeNewswire EN)
|
|
|
BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced first-in-human clinical data for LB2102, its investigational DLL3-targeted CAR-T cell therapy for patients with relapsed or refractory small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC). The data demonstrate early evidence of clinical activity and a manageable safety profile. At higher dose levels, an objective response rate (ORR) of 28.6% and disease control rate (DCR) of 78.6% were observed, including durable responses in some heavily pretreated patients....
|
|
|
|
|
21.05.26 - 23:03
|
Legend Biotech Announces Presentations at ASCO 2026 (GlobeNewswire EN)
|
|
|
SOMERSET, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including a rapid oral presentation highlighting preliminary Phase 1 data for LB2102, its investigational DLL3-targeted CAR-T therapy for relapsed or refractory small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC)....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.04.26 - 16:45
|
GENSCRIPT BIOTECH 1Q26 CARVYKTI Net Sales USD597M, Up 61.8% YoY (AAStocks)
|
|
|
GENSCRIPT BIOTECH (01548.HK) announced that its subsidiary Legend Biotech, pursuant to its collaboration and license agreement with Janssen Biotech, recorded net trade sales of approximately USD597 million for CARVYKTI in 1Q26, representing a YoY increase of 61.8%. (de/d)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis arti......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
